Cargando…
Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis
BACKGROUND: For the management of immune checkpoint inhibitor (ICI)-induced pneumonitis (ICI-pneumonitis), discontinuation of ICIs and high dose corticosteroid based on grade are generally recommended. The purpose of this study is to describe management and outcome of ICI-pneumonitis and explore wha...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890388/ https://www.ncbi.nlm.nih.gov/pubmed/31803501 http://dx.doi.org/10.1136/esmoopen-2019-000575 |
_version_ | 1783475603579600896 |
---|---|
author | Park, Changhee Keam, Bhumsuk Yoon, Soon Ho Ock, Chan-Young Choi, Sun Mi Kim, Miso Park, Young Sik Kim, Tae Min Oh, Do-Youn Kim, Dong-Wan Kim, Young Whan Heo, Dae Seog Bang, Yung-Jue |
author_facet | Park, Changhee Keam, Bhumsuk Yoon, Soon Ho Ock, Chan-Young Choi, Sun Mi Kim, Miso Park, Young Sik Kim, Tae Min Oh, Do-Youn Kim, Dong-Wan Kim, Young Whan Heo, Dae Seog Bang, Yung-Jue |
author_sort | Park, Changhee |
collection | PubMed |
description | BACKGROUND: For the management of immune checkpoint inhibitor (ICI)-induced pneumonitis (ICI-pneumonitis), discontinuation of ICIs and high dose corticosteroid based on grade are generally recommended. The purpose of this study is to describe management and outcome of ICI-pneumonitis and explore what to consider when managing ICI-pneumonitis with or without corticosteroids in addition to grade. METHODS: We reviewed data of 706 cancer patients who were treated with ICIs and identified radiographically proven pneumonitis. The diagnosis of ICI-pneumonitis was established after excluding alternative aetiologies either by a bronchoscopy or a thorough examination of clinical features. The evaluation of the management and outcome of pneumonitis were evaluated according to the time of corticosteroid administration. RESULTS: ICI-pneumonitis developed in 16 patients (2.3%); nine grade 1, four grade 2 and three grade 3. Initially, 10 patients were spared from corticosteroid administration; fourpatients eventually received corticosteroid after 4 weeks of pneumonitis diagnosis due to clinical, radiographical aggravation and/or clinicians’ decision. The other sixpatients never received corticosteroid and improved or remained stable radiographically. When the four and sixpatients were compared, pneumonitis grade was similar, while the latter sixpatients had a later onset from initiation of ICIs (mean 37.48 weeksvs25.45 weeks), more prior lines of chemotherapy (median 2.5 vs 1.0 lines), higher proportion of current/ex-smokers (83.3% vs 50.0%), and fewer other accompanying immune-related adverse events (50% vs 75%). Time to improvement of pneumonitis was similar between the fourpatients who received delayed corticosteroid and fivepatients who received corticosteroid within 4 weeks(3.6 vs 2.5 weeks). CONCLUSIONS: Our analyses provide clinical insights that stratification of the patients is important in managing ICI-pneumonitis. Along with ICI-pneumonitis grade, more factors associated with the outcome need to be unravelled in the future. |
format | Online Article Text |
id | pubmed-6890388 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-68903882019-12-04 Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis Park, Changhee Keam, Bhumsuk Yoon, Soon Ho Ock, Chan-Young Choi, Sun Mi Kim, Miso Park, Young Sik Kim, Tae Min Oh, Do-Youn Kim, Dong-Wan Kim, Young Whan Heo, Dae Seog Bang, Yung-Jue ESMO Open Original Research BACKGROUND: For the management of immune checkpoint inhibitor (ICI)-induced pneumonitis (ICI-pneumonitis), discontinuation of ICIs and high dose corticosteroid based on grade are generally recommended. The purpose of this study is to describe management and outcome of ICI-pneumonitis and explore what to consider when managing ICI-pneumonitis with or without corticosteroids in addition to grade. METHODS: We reviewed data of 706 cancer patients who were treated with ICIs and identified radiographically proven pneumonitis. The diagnosis of ICI-pneumonitis was established after excluding alternative aetiologies either by a bronchoscopy or a thorough examination of clinical features. The evaluation of the management and outcome of pneumonitis were evaluated according to the time of corticosteroid administration. RESULTS: ICI-pneumonitis developed in 16 patients (2.3%); nine grade 1, four grade 2 and three grade 3. Initially, 10 patients were spared from corticosteroid administration; fourpatients eventually received corticosteroid after 4 weeks of pneumonitis diagnosis due to clinical, radiographical aggravation and/or clinicians’ decision. The other sixpatients never received corticosteroid and improved or remained stable radiographically. When the four and sixpatients were compared, pneumonitis grade was similar, while the latter sixpatients had a later onset from initiation of ICIs (mean 37.48 weeksvs25.45 weeks), more prior lines of chemotherapy (median 2.5 vs 1.0 lines), higher proportion of current/ex-smokers (83.3% vs 50.0%), and fewer other accompanying immune-related adverse events (50% vs 75%). Time to improvement of pneumonitis was similar between the fourpatients who received delayed corticosteroid and fivepatients who received corticosteroid within 4 weeks(3.6 vs 2.5 weeks). CONCLUSIONS: Our analyses provide clinical insights that stratification of the patients is important in managing ICI-pneumonitis. Along with ICI-pneumonitis grade, more factors associated with the outcome need to be unravelled in the future. BMJ Publishing Group 2019-11-28 /pmc/articles/PMC6890388/ /pubmed/31803501 http://dx.doi.org/10.1136/esmoopen-2019-000575 Text en © Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Original Research Park, Changhee Keam, Bhumsuk Yoon, Soon Ho Ock, Chan-Young Choi, Sun Mi Kim, Miso Park, Young Sik Kim, Tae Min Oh, Do-Youn Kim, Dong-Wan Kim, Young Whan Heo, Dae Seog Bang, Yung-Jue Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis |
title | Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis |
title_full | Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis |
title_fullStr | Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis |
title_full_unstemmed | Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis |
title_short | Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis |
title_sort | clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890388/ https://www.ncbi.nlm.nih.gov/pubmed/31803501 http://dx.doi.org/10.1136/esmoopen-2019-000575 |
work_keys_str_mv | AT parkchanghee clinicalinsightsonoutcomesofcorticosteroidadministrationinimmunecheckpointinhibitorinducedpneumonitisbyretrospectivecaseseriesanalysis AT keambhumsuk clinicalinsightsonoutcomesofcorticosteroidadministrationinimmunecheckpointinhibitorinducedpneumonitisbyretrospectivecaseseriesanalysis AT yoonsoonho clinicalinsightsonoutcomesofcorticosteroidadministrationinimmunecheckpointinhibitorinducedpneumonitisbyretrospectivecaseseriesanalysis AT ockchanyoung clinicalinsightsonoutcomesofcorticosteroidadministrationinimmunecheckpointinhibitorinducedpneumonitisbyretrospectivecaseseriesanalysis AT choisunmi clinicalinsightsonoutcomesofcorticosteroidadministrationinimmunecheckpointinhibitorinducedpneumonitisbyretrospectivecaseseriesanalysis AT kimmiso clinicalinsightsonoutcomesofcorticosteroidadministrationinimmunecheckpointinhibitorinducedpneumonitisbyretrospectivecaseseriesanalysis AT parkyoungsik clinicalinsightsonoutcomesofcorticosteroidadministrationinimmunecheckpointinhibitorinducedpneumonitisbyretrospectivecaseseriesanalysis AT kimtaemin clinicalinsightsonoutcomesofcorticosteroidadministrationinimmunecheckpointinhibitorinducedpneumonitisbyretrospectivecaseseriesanalysis AT ohdoyoun clinicalinsightsonoutcomesofcorticosteroidadministrationinimmunecheckpointinhibitorinducedpneumonitisbyretrospectivecaseseriesanalysis AT kimdongwan clinicalinsightsonoutcomesofcorticosteroidadministrationinimmunecheckpointinhibitorinducedpneumonitisbyretrospectivecaseseriesanalysis AT kimyoungwhan clinicalinsightsonoutcomesofcorticosteroidadministrationinimmunecheckpointinhibitorinducedpneumonitisbyretrospectivecaseseriesanalysis AT heodaeseog clinicalinsightsonoutcomesofcorticosteroidadministrationinimmunecheckpointinhibitorinducedpneumonitisbyretrospectivecaseseriesanalysis AT bangyungjue clinicalinsightsonoutcomesofcorticosteroidadministrationinimmunecheckpointinhibitorinducedpneumonitisbyretrospectivecaseseriesanalysis |